Discussion
Coronavirus disease 2019 (COVID-19), which was identified due to the case of viral pneumonia in 2019, and was named by the world health organization on January 12, 2020[1].Coronavirus is a large family of viruses known to cause serious illnesses such as MERS and SARS[5].The novel coronavirus is a new strain of coronavirus that has never been found in humans before.Since December 2019, A lot of viral pneumonia cases have been detected, which have been diagnosed as viral pneumonia infection.People infected with coronavirus after the common signs of respiratory symptoms, fever, cough, gas and breathing difficulties.In more severe cases, the infection can lead to pneumonia, severe acute respiratory syndrome, kidney failure, and even death[6, 7].There is no specific treatment for diseases caused by novel coronaviruses currently[8]. The generally susceptible and high mortality associated with COVID-19 led us to conduct this systematic review and meta-analysis to summarize the available options for treatment of novel coronavirus infection based on previous reports of therapy of SARS,MERS.
Convalescent plasma plays an important role in the treatment of SARS and MERS for severe respiratory infections[9].Cheng [10]found that convalescent plasma therapy had benefits effect for SARS,especialy in the early phase. Soo[11]Conformed that Patients with convalescent plasma therapy had a shorter hospital stay, lower mortality and no immediate adverse effects were observed. Yeh[12]made a conclusion that infected SARS in Taiwan hospital whose condition had progressed severely survived after transfusion with convalescent plasma. Chun [13]reported Transfusion-Related Acute Lung Injury occured afer Convalescent Plasma Transfusion in a Patient With Middle East Respiratory Syndrome. Jae-Hoon Ko[14] reported donor convalescent plasma with a neutralization activity of a PRNT titer 1:80 should be used in MERS.
This study revealed that the therapy of Convalescent plasma can reduce mortality of patients with Coronavirus.The study provided a high sample size and the conclusions drawn by the study are highly credible because of the comprehensive data collection strategy. However,there were several limitations to this study. The distribution of studies between locations was not uniform. we were able to find and extract data for the meta-analysis from Hong Kong, Taiwan, Korea. In additional , most of the selected studies were from hospital and no strict control group. There was no convalescent plasma for the treatment of patients with Coronavirus in the early stages. there may be reporting bias in some details. Moreover,The systematic review is likely to have publication bias as some articals used other languages .Therefore, the conclusions of this Meta-analysis still need to be verified by further studies to clarify the associations.
We hope this study will provide important information for policy-makers pay more attention to The effectiveness of convalescent plasma for the treatment of patients with Coronavirus , Improve survival of critically ill patients[15].
Acknowledgements: The authors declare no conflict of interest in this study.
References
[1] S. Dong, J. Sun, Z. Mao, L. Wang, Y.L. Lu, J. Li, A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV), Journal of medical virology, (2020).
[2] X.Y. Li, B. Du, Y.S. Wang, H.Y.J. Kang, F. Wang, B. Sun, H.B. Qiu, Z.H. Tong, [The keypoints in treatment of the critical coronavirus disease 2019 patient], Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 43 (2020) E026.
[3] C. Chen, X.R. Zhang, Z.Y. Ju, W.F. He, [Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies], Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns, 36 (2020) E005.
[4] H. Momattin, K. Mohammed, A. Zumla, Z.A. Memish, J.A. Al-Tawfiq, Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)–possible lessons from a systematic review of SARS-CoV therapy, Int J Infect Dis, 17 (2013) e792-798.
[5] J.A. Al-Tawfiq, Viral loads of SARS, MERS and SARS-CoV-2 in respiratory specimens: What have we learned?, Travel medicine and infectious disease, (2020) 101629.
[6] G.Q. Qian, N.B. Yang, F. Ding, A.H.Y. Ma, Z.Y. Wang, Y.F. Shen, C.W. Shi, X. Lian, J.G. Chu, L. Chen, Z.Y. Wang, D.W. Ren, G.X. Li, X.Q. Chen, H.J. Shen, X.M. Chen, Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series, QJM : monthly journal of the Association of Physicians, (2020).
[7] Z. Wang, B. Yang, Q. Li, L. Wen, R. Zhang, Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, (2020).
[8] A.C. Cunningham, H.P. Goh, D. Koh, Treatment of COVID-19: old tricks for new challenges, Critical care (London, England), 24 (2020) 91.
[9] Y.M. Arabi, A.H. Hajeer, T. Luke, K. Raviprakash, H. Balkhy, S. Johani, A. Al-Dawood, S. Al-Qahtani, A. Al-Omari, F. Al-Hameed, F.G. Hayden, R. Fowler, A. Bouchama, N. Shindo, K. Al-Khairy, G. Carson, Y. Taha, M. Sadat, M. Alahmadi, Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia, Emerg Infect Dis, 22 (2016) 1554-1561.
[10] Y. Cheng, R. Wong, Y.O. Soo, W.S. Wong, C.K. Lee, M.H. Ng, P. Chan, K.C. Wong, C.B. Leung, G. Cheng, Use of convalescent plasma therapy in SARS patients in Hong Kong, Eur J Clin Microbiol Infect Dis, 24 (2005) 44-46.
[11] <soo2004.pdf>.
[12] K.M. Yeh, T.S. Chiueh, L.K. Siu, J.C. Lin, P.K. Chan, M.Y. Peng, H.L. Wan, J.H. Chen, B.S. Hu, C.L. Perng, J.J. Lu, F.Y. Chang, Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital, J Antimicrob Chemother, 56 (2005) 919-922.
[13] S. Chun, C.R. Chung, Y.E. Ha, T.H. Han, C.S. Ki, E.S. Kang, J.K. Park, K.R. Peck, D. Cho, Possible Transfusion-Related Acute Lung Injury Following Convalescent Plasma Transfusion in a Patient With Middle East Respiratory Syndrome, Ann Lab Med, 36 (2016) 393-395.
[14] J.H. Ko, H. Seok, S.Y. Cho, Y.E. Ha, J.Y. Baek, S.H. Kim, Y.J. Kim, J.K. Park, C.R. Chung, E.S. Kang, D. Cho, M.A. Muller, C. Drosten, C.I. Kang, D.R. Chung, J.H. Song, K.R. Peck, Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience, Antiviral therapy, 23 (2018) 617-622.
[15] G.J.G. Asmundson, S. Taylor, How health anxiety influences responses to viral outbreaks like COVID-19: What all decision-makers, health authorities, and health care professionals need to know, Journal of anxiety disorders, 71 (2020) 102211.